Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eucalyptol SCHEMBL17836873 | 1.00 | LMNA (1.00) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL19622 | 1.00 | LMNA (1.00) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL41020 | 1.00 | LMNA (1.00) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL21462060 | 0.97 | LMNA (0.95) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL1492188 | 0.93 | LMNA (0.86) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL6122971 | 0.87 | LMNA (0.75) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL17022815 | 0.87 | MAPK1 (0.75) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL19474967 | 0.85 | LMNA (0.72) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL9791399 | 0.85 | MAPK1 (0.72) | LMNAMAPTTSHRMAPK1RECQL | |
| Eucalyptol SCHEMBL5324431 | 0.85 | LMNA (0.72) | LMNAMAPTTSHRMAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140248227-A1 | DEODORIZING COMPOSITIONS | HENKEL AG & CO. KGAA (DE) | 2014-09-04 | — | — | US | claimed |
| EP-3463479-A2 | PHARMACEUTICAL FORMULATION COMPRISING CINEOL AND AMOXICILLIN | Advanced Scientific Developements (MA) | 2019-04-10 | — | — | EP | disclosed |
| EP-2648704-B1 | ANTI-MICROBIAL COMPOSITION | SEPTEOS (FR) | 2019-01-16 | — | — | EP | disclosed |
| EP-3365418-A2 | PARTICLES FOR MALODOR REDUCTION | The Procter and Gamble Company (US) | 2018-08-29 | — | — | EP | disclosed |
| EP-3310888-A1 | PERFUME COMPOSITIONS | The Procter and Gamble Company (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-3197510-A1 | DELIVERY SYSTEMS COMPRISING MALODOR REDUCTION COMPOSITIONS | The Procter & Gamble Company (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197422-A1 | CLEANING AND/OR TREATMENT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | The Procter & Gamble Company (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197423-A1 | PRODUCTS COMPRISING MALODOR REDUCTION MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197508-A1 | ANTIPERSPIRANT AND DEODORANT COMPOSITIONS COMPRISING MALODOR REDUCTION COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | disclosed |
| EP-3197426-A1 | FRESHENING COMPOSITIONS AND DEVICES COMPRISING SAME | THE PROCTER & GAMBLE COMPANY (US) | 2017-08-02 | — | — | EP | disclosed |
| WO-2011117424-A1 | VIRAL INHIBITOR COMPOSITIONS FOR IN VIVO THERAPEUTIC USE COMPRISING A COMBINATION OF (-) -CARVONE, GERANIOL AND A FURTHER ESSENTIAL OIL COMPONENT | CESA ALLIANCE S.A. (LU) | 2011-09-29 | — | — | WO | disclosed |
| WO-2011056935-A1 | DELIVERY PARTICLE | THE PROCTER & GAMBLE COMPANY (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011006183-A1 | CINEOLE | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2011-01-20 | — | — | WO | disclosed |
| EP-1894603-A1 | Encapsulation of bulky fragrance molecules | Takasago International Corporation (JP) | 2008-03-05 | — | — | EP | disclosed |
| US-6121234-A | ORALLY COADMINISTERING TO MAMMAL PHARMACEUTICAL COMPOUND AND ESSENTIAL OIL | AVMAX, INC. (US) | 2000-09-19 | — | — | US | disclosed |
| US-5889049-A | ADMINISTERING A THERAPEUTICAL COMPOUND COMPRISING A SATURATED MONO OR BICYCLIC TERPENE-ALCOHOL,-ETHER,-KETONE AND -THIOL WHICH SUPPRESSES RELEASE AND PRODUTION OF CYTOKINES AND INFLAMMATORY MEDIATOR FROM HUMAN CELLS ; ANTIASTHMA AGENT | JUERGENS UWE R (DE) | 1999-03-30 | — | — | US | disclosed |
| US-5716928-A | ADMINISTERING DRUG CONCURRENTLY WITH ESSENTIAL OIL | AVMAX, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5665386-A | Use of essential oils to increase bioavailability of oral pharmaceutical compounds | AVMAX, INC. (US) | 1997-09-09 | — | — | US | disclosed |
| EP-0654994-A1 | USE OF TERPENE COMPOUNDS FOR REDUCED RELEASE OF ARACHIDONIC ACID AND OF INFLAMMATION MEDIATORS | JUERGENS, Uwe R. (DE) | 1995-05-31 | — | — | EP | disclosed |
| WO-1994028895-A2 | USE OF TERPENE COMPOUNDS FOR REDUCED RELEASE OF ARACHIDONIC ACID AND OF INFLAMMATION MEDIATORS | JUERGENS UWE R (DE) | 1994-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248227-A1 | DEODORIZING COMPOSITIONS | ODC1, LIPC, C1S | LMNA 1318/4885MAPT 2809/4885TSHR 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.